1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Laseroptek Co., Ltd.

Laseroptek Co., Ltd.

KKRX:199550
2,790.00
KRW
-185.00
(-6.22%)
-531.05EPS
50.10BMarket Cap
2015 Y
2016 Y
2017 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
64,902.88
116,909.18
108,651.59
12,320.77
18,241.18
28,177.82
3,791.95
2,656.62
1,958.19
2,360.31
Basic EPS, GAAP
-13,542.24
-4,629.22
-5,966.66
-3,036.13
-1,236.5
2,640.64
1.85
-62.98
-818.77
-531.05
Free Cash Flow per Basic Share
-23,793.63
-20,075.67
-3,124.84
-608.96
-1,926.09
477.13
-51.62
-365.89
-541.6
-423.71
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
24.6
64.03
23.24
-266.79
-362.65
1,110.89
1,849.93
2,416.31
1,808.64
2,024.79
Tangible Book Value per Share
-73.8
-36.95
-79.22
-276.63
-395.38
1,050.17
1,787.88
2,359.01
1,757.64
1,953.81
Basic Weighted Avg Shares
- -
- -
- -
1
1
1
9
12
13
13
Sales/Revenue/Turnover
5,559
10,316
10,057
11,938
18,652
30,049
34,352
33,038
25,695
31,679
Operating Margin (%)
-18.8
1.1
1.71
-5.35
3.48
8.35
13.04
-0.59
-46.88
-32.84
Depreciation Expense
336
445
463
557
793
1,117
1,327
1,545
1,770
1,674
Net Income, GAAP
-1,160
-408
-552
-2,942
-1,264
2,816
17
-783
-10,744
-7,127
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-20.87
-3.96
-5.49
-24.64
-6.78
9.37
0.05
-2.37
-41.81
-22.5
Working Capital
3,305
531
-1,588
-4,633
-5,911
5,977
13,752
23,598
14,856
21,904
LT Debt
3,525
250
800
3,325
3,490
2,255
2,051
3,951
2,818
2,745
Total Equity
347
775
252
-2,896
-3,936
12,057
20,078
30,461
22,182
30,056
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-84.93
-116.61
- -
- -
- -
0.1
-3.1
-40.82
-24.74

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
7,226
8,212
8,252
LT Borrowings
- -
- -
- -
LT Finance Leases
2,818
2,854
2,745
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
15
Market Capitalization
62,476
65,614
50,099

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
26,214
24,877
35,235
Cash, Cash Equivalents & STI
5,515
5,770
16,822
Accounts Receivable, Net
7,815
7,224
8,203
Inventories
11,976
11,032
9,674
Total Current Liabilities
11,357
11,373
13,332
Payables & Accruals
- -
- -
- -
ST Debt
7,226
8,212
8,252
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-55.86%
-27.18%
Free Cash Flow
- -
169.05%
56.19%
Net Income, GAAP
- -
-794.96%
1,271.71%
Sales/Revenue/Turnover
- -
21.12%
-22.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,178
10,355
7,288
7,218
33,038
2025
5,267
3,900
9,873
6,656
25,695
2026
6,362
8,788
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-213.14
160.24
-35.2
17.89
-62.98
2025
-211.18
-216.73
-198.61
-191.09
-818.77
2026
-96.08
-52
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
Full Time Employees
93
Sector
Health technology
Industry
Medical specialties
Address
Seongnam-si South Korea
IPO Date
Feb 1, 2024
Website
laseroptek.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Laseroptek Co., Ltd. is a South Korea-based medical technology company that develops, manufactures, and commercializes advanced laser systems for aesthetic and medical dermatological applications. Founded in 2000 and headquartered in Seongnam-si, South Korea, the company operates globally across North America, Europe, Asia-Pacific, and the Middle East, supported in the Western Hemisphere by its regional subsidiary, Laseroptek America Corp. Laseroptek operates primarily through its Medical Laser Device segment, catering to dermatologists, plastic surgeons, and aesthetic clinics. The company's core product portfolio includes the PALLAS and PALLAS Premium series, comprising solid-state 311nm and 308nm UVB lasers indicated for the treatment of skin disorders such as vitiligo, psoriasis, atopic dermatitis, and leukoderma; the PicoLO and PicoLO Premium series, offering high-stability Nd:YAG picosecond laser systems utilized for tattoo removal, pigmented lesion clearance, acne scar revision, and skin rejuvenation; the HELIOS series, including the HELIOS III and HELIOS 785 Pico, which integrate Q-switched and picosecond Nd:YAG laser technologies for treating complex pigmented lesions, melasma, and skin toning; the LOTUS series, featuring Er:YAG fractional lasers designed for ablative skin resurfacing and scar repair; the HYPERION series of long-pulse Nd:YAG lasers engineered for vascular lesions and hair reduction; and the ZELOS long-pulse Alexandrite laser platform. In recent developments, Laseroptek achieved a public listing on the KOSDAQ market (KRX: 199550) in February 2024 via a merger with Hana Financial 23rd SPAC. The company has also expanded its regulatory footprint by securing multiple U.S. FDA 510(k) clearances, notably for its HELIOS 785 Pico and upgraded solid-state platforms, while broadening its international distribution network through expanded commercial partnerships across the United States and the Asia-Pacific region.